Why is Jagsonpal Pharma falling/rising?

As of 19-Sep, Jagsonpal Pharmaceuticals Ltd is currently priced at 242.50, reflecting a decrease of 1.8, or 0.74%. The stock has underperformed its sector today by 1.01%, and while it is trading above its 20-day, 100-day, and 200-day moving averages, it is below its 5-day and 50-day moving averages. Additionally, there has been a notable decline in investor participation, with delivery volume falling by 56.54% compared to the 5-day average. Over the past week, the stock has gained 0.33%, but it has experienced a decline of 2.26% over the past month, contrasting with a 48.75% increase over the last year, indicating strong long-term performance despite recent short-term challenges.
Broader Market Context: The Sensex has increased by 0.88% over the past week, suggesting that the broader market is performing better than Jagsonpal Pharmaceuticals in the short term. Despite the recent price decline, the company has demonstrated healthy long-term growth, with a low debt-to-equity ratio and consistent positive results over the last five quarters. The operating profit has grown at an annual rate of 42.31%, and the stock has outperformed the BSE500 over the last three years, one year, and three months. This indicates that while the stock is currently facing some short-term pressures, its long-term fundamentals remain strong.